FDA gives Merck priority review for blood vessel disorder therapy sotatercept

The Food and Drug Administration granted Merck priority review for its hypertension treatment sotatercept, following the results from the Phase 3 STELLAR trial, the company announced Thursday.

Sotatercept is a novel investigational activin signaling inhibitor targeting pulmonary arterial hypertension (PAH), a rare and progressive disease that causes the narrowing of blood vessels in the lungs.